Tuoxin Pharmaceutical: Announcement on Subsidiary Obtaining Drug Production License
Securities code: 301089 Securities abbreviation: Tuoxin Pharmaceutical Announcement number: 2026-005
Tuoxin Pharmaceutical Group Co., Ltd.
Announcement on Subsidiary Obtaining Drug Production License
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Xinxiang Jingquan Biotechnology Co., Ltd. (hereinafter referred to as "Jingquan Biotechnology"), a wholly-owned subsidiary of Tuoxin Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company"), recently successfully obtained the "Drug Production License" issued by the Henan Provincial Food and Drug Administration. The relevant qualification information and impact on the company are announced as follows:
1. Basic information of "Drug Production License"
Company name: Xinxiang Jingquan Biotechnology Co., Ltd.
Unified social credit code: 914110700MA9L9KWXJ
Residence (business place): No. 266, Jingquan East Road, High-tech Zone, Xinxiang City, Henan Province
License number: Yu 20260007
Category code: Dh
Legal representative: Liu Deqian
Person in charge of the company: Liu Deqian
Quality manager: Wang Zanbo
Valid until: February 12, 2031
Production address and production scope: No. 266, Jingquan East Road, High-tech Zone, Xinxiang City, Henan Province: API (Coenzyme Q10)***
2. The impact of obtaining the license this time on the company
This is the first time that Jingquan Biotech has obtained the "Drug Production License". The acquisition of this qualification marks that the company's coenzyme Q10 API-related products have officially met the qualifications for compliant production and meet the industry regulatory requirements for pharmaceutical production. This qualification will further enrich and optimize the company's product structure, and will play an important and positive role in promoting the layout and long-term development of the company's health business sector.
3. Risk warning
The pharmaceutical industry is affected by multiple factors such as policy supervision and changes in the market environment. There is a certain degree of uncertainty in the production organization and market sales of API products. Investors are kindly requested to pay full attention to investment risks, make rational judgments and make prudent decisions.
4. Documents for reference
Xinxiang Jingquan Biotechnology Co., Ltd. "Drug Production License"
Announcement is hereby made.
Tuoxin Pharmaceutical Group Co., Ltd. Board of Directors
February 25, 2026